Novo Nordisk Stock - Deutsche Bank reiterates Hold rating

Novo Nordisk stays on Deutsche Bank’s Hold list as the bank reiterates its rating and price target on the Danish drugmaker. On Friday we also take a closer look at how the stock has compared with other big pharma names this week.

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 21:39 CET. Details in the imprint.

Novo Nordisk (DK0062498333) remains rated Hold at Deutsche Bank, with the analyst house confirming its stance and price target on the Danish pharmaceutical group this week. The reaffirmation was noted in an update on Nasdaq Copenhagen’s quote page on 06/19/2026.

What Deutsche Bank signals

On Friday afternoon, Nasdaq Copenhagen’s overview for Novo Nordisk showed Deutsche Bank reiterating its Hold rating with a price target of DKK 290 on the B shares. The brief note was time-stamped at 03:29 p.m. local time on 06/19/2026.

The affirmation keeps Novo Nordisk in neutral territory at the German bank, which has not shifted to a Buy stance despite strong demand for obesity and diabetes treatments. The DKK 290 target implies only limited upside from recent trading levels on the Danish line.

Where consensus stands this week

Across the broader analyst community, Novo Nordisk continues to command a predominantly positive view. Data compiled by Investing.com show an average 12-month price target around DKK 312.90 from 24 analysts for the B share line in Copenhagen. Consensus figures from Investing.com

Within that group, the highest target reaches DKK 454, while the lowest sits at DKK 200, highlighting a wide dispersion of expectations around growth and profitability. A sizeable number of brokers still rate the stock Buy or equivalent, while a smaller camp remains at Hold.

Sector comparison over the week

This week, Novo Nordisk shares have traded broadly in line with other large-cap European and US pharma names. Initial quote data from MarketBeat show the New York-listed NVO American depositary shares closing at $43.20 on 06/18/2026, essentially flat on the day. MarketBeat quote for NVO

Peers such as Eli Lilly, Sanofi and AstraZeneca also saw muted day-to-day moves during the week, with no major sector-wide catalyst. Against this backdrop, Deutsche Bank’s unchanged Hold stance fits a cautious, wait-and-see tone in parts of the analyst community.

What the company sells

Novo Nordisk generates most of its revenue from treatments for diabetes and obesity, led by GLP-1 based therapies. Flagship brands include the type 2 diabetes drug Ozempic and the weight-loss injection Wegovy, alongside long-established insulin products and a smaller rare-disease portfolio.

Where the stock trades today

The B shares of Novo Nordisk (DK0062498333) trade on Nasdaq Copenhagen at around DKK 285.00 as of 06/19/2026, 17:30 CEST.

Key facts on Novo Nordisk stock

• Company: Novo Nordisk A/S
• ISIN: DK0062498333
• WKN: A3EDE1
• Ticker: NOVO-B (Copenhagen), NVO (NYSE ADR)
• Venue: Nasdaq Copenhagen
• Price (as of 06/19/2026, 17:30 CEST): 285.00 DKK
• Market cap: approximately 1,250,000,000,000 DKK (as of 06/19/2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: OMX Copenhagen 25, STOXX Europe 50
• Next earnings date: 08/07/2026

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.